Tianjin Med J ›› 2016, Vol. 44 ›› Issue (2): 200-204.doi: 10.11958/58911

Previous Articles     Next Articles

EML4-ALK and EGFR mutation status and survival analysis in Uygur with stage Ⅳ NSCLC

WANG Qiang1ZHANG Qiao1CAO Yanzhen2TAO Jie1SHAN Li1△#br#   

  1. 1 Department of Medical Oncology, 2 Department of Pathology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China
  • Received:2015-05-08 Revised:2015-07-07 Published:2016-02-15 Online:2016-02-15
  • Contact: △Corresponding Author E-mail: shanlinew319@163.com E-mail:taojie0309@163.com

Abstract: Objective To investigate the relationship between the echinoderm microtubule associated protein like 4- anaplastic lymphoma kinase (EML4-ALK) and epithelial growth factor receptor (EGFR) mutation status and overall survival (OS) in Uygur patients with stage Ⅳ non-small cell lung cancer (NSCLC) who did not accept tyrosine kinase inhibitor treatment. Methods Totally 97 tissue samples were collected from Uygur patients with stage Ⅳ NSCLC who did not accept tyro⁃ sine kinase inhibitor treatment. EML4-ALK fusion gene and EGFR mutation status were detected by using FISH and ARMS methods. The survival rates were analysed. Results In 97 tissue samples, EML4-ALK fusion genes were found in 6 (6.2%) samples, EGFR mutations were found in 26 (26.8%) samples. The survival analysis showed that there was no significant difference in OS between EML4-ALK fusion gene group and no EML4-ALK fusion gene group (P=0.941). There was no significant difference in OS between EGFR mutation group and wild-type EGFR group (P=0.607). The values of median OS were 17.7 months, 17.3 months and 16.2 months for EGFR mutant group, EML4-ALK positive group and EML4-ALK negative+ EGFR wild-type group, and thre was no significant difference between them (P=0.915). Conclusion Excluding the thera⁃ peutic influence in TKIs, EML4-ALK fusion gene and EGFR mutation status of tumor tissue can not be used as an indepen⁃ dent factor in assessing the prognosis in Uygur patients with stage Ⅳ NSCLC.

Key words: carcinoma, non-small-cell lung, receptor, epidermal growth factor, mutation, UYGUR NATIONALITY, non-small cell lung cancer, EML4-ALK, survival analysis